References
Consumer Reports.org. Deadly infections: how good is your hospital at preventing them? Available at: http://www.consumerreports.org/cro/2012/12/deadly-infections/index.htm. Accessed February 17, 2013.
Ghert M, Deheshi B, Holt G, Randall RL, Ferguson P, Wunder J, Turcotte R, Werier J, Clarkson P, Damron T, Benevenia J, Anderson M, Gebhardt M, Isler M, Mottard S, Healey J, Evaniew N, Racano A, Sprague S, Swinton M, Bryant D, Thabane L, Guyatt G, Bhandari M; PARITY Investigators. Prophylactic antibiotic regimens in tumour surgery (PARITY): protocol for a multicentre randomised controlled study. BMJ Open. 2012;2(6). pii: e002197.
Hardes J, Ahrens H, Gebert C, Streitbuerger A, Buerger H, Erren M, Gunsel A, Wedemeyer C, Saxler G, Winkelmann W, Gosheger G. Lack of toxicological side-effects in silver-coated megaprostheses in humans. Biomaterials. 2007;28:2869–2875.
Jeys LM, Grimer RJ, Carter SR, Tillman RM, Abudu A. Post operative infection and increased survival in osteosarcoma patients: are they associated? Ann Surg Oncol. 2007;14:2887–2895.
McMullen L. U.S. News Ranks Best Hospitals 2012–2013. July 16, 2012. Available at: http://health.usnews.com/health-news/best-hospitals/articles/2012/07/16/us-news-ranks-best-hospitals-2012-13. Accessed February 21, 2013.
Racano A, Pazionis T, Farrokhyar F, Deheshi B, Ghert M. High infection rate outcomes in long-bone tumor surgery with endoprosthetic reconstruction in adults: a systematic review. Clin Orthop Relat Res. 2013 Feb 12. [Epub ahead of print].
Stewart S, Barr S, Engiles J, Hickok NJ, Shapiro IM, Richardson DW, Parvizi J, Schaer P. Vancomycin-modified implant surface inhibits biofilm formation and supports bone-healing in an infected osteotomy model in sheep: a proof-of-concept study. J Bone Joint Surg Am. 2012;94:1406–1415.
Tsuchiya H, Shirai T, Nishida H, Murakami H, Kabata T, Yamamoto N, Watanabe K, Nakase J. Innovative antimicrobial coating of titanium implants with iodine. J Orthop Sci. 2012;17:595–604.
Author information
Authors and Affiliations
Corresponding author
Additional information
This CORR Insights™ is a commentary on the article “High Infection Rate Outcomes in Long-bone Tumor Surgery with Endoprosthetic Reconstruction in Adults: A Systematic Review” by Racano and colleagues available at DOI 10.1007/s11999-013-2842-9.
The author certifies that he, or a member of his or her immediate family, has no funding or commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article. The author is the President of the Musculoskeletal Tumor Society, the sponsor of the Parity clinical trial referred to in this commentary, and a coauthor of an article referenced that describes the methodology for developing that trial.
All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research editors and board members are on file with the publication and can be viewed on request.
This CORR Insights™ comment refers to the article available at DOI: 10.1007/s11999-013-2842-9
About this article
Cite this article
Healey, J.H. CORR Insights™: High Infection Rate Outcomes in Long-bone Tumor Surgery with Endoprosthetic Reconstruction in Adults: A Systematic Review. Clin Orthop Relat Res 471, 2028–2029 (2013). https://doi.org/10.1007/s11999-013-2893-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11999-013-2893-y